News coverage about Valeritas (NASDAQ:VLRX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Valeritas earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.773103007706 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Valeritas (NASDAQ:VLRX) traded up $0.12 on Thursday, hitting $3.29. The stock had a trading volume of 22,300 shares, compared to its average volume of 20,157. The firm has a market capitalization of $21.68, a PE ratio of -0.20 and a beta of 7.78. Valeritas has a twelve month low of $2.00 and a twelve month high of $40.00. The company has a debt-to-equity ratio of 3.54, a current ratio of 3.88 and a quick ratio of 3.20.
Separately, ValuEngine upgraded Valeritas from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st.
TRADEMARK VIOLATION WARNING: “Valeritas (VLRX) Getting Somewhat Positive Media Coverage, Study Finds” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-valeritas-vlrx-stock-price.html.
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.